Insights from Pharma 2025: Navigating the evolution of EU Health Technology Assessment (HTA) Regulation
These conversations reflect the pulse of an industry in motion, committed to driving smarter, more sustainable healthcare solutions in an increasingly complex world. Whether focused on regulatory evolution, market access, technological breakthroughs, or cross-sector collaboration, each expert offered a unique lens on how pharma is adapting to meet the needs of tomorrow.
EUCOPE, representing 170 innovative pharma and biotech companies, plays a crucial role in shaping the EU HTA landscape. By working closely with other trade organizations, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Alliance for Regenerative Medicine (ARM), and EuropaBio, EUCOPE ensures the industry's voice is heard in Brussels, particularly for small to mid-sized pharma and biotech companies.
Understanding the EU HTA regulation
The EU HTA regulation, which came into effect in January 2025, marks a significant step toward harmonizing HTAs across Europe. Initially focusing on oncology therapies and advanced therapy medicinal products (ATMPs), the regulation aims to streamline the clinical assessment process through the joint clinical assessment (JCA) and to offer companies to engage in an early development phase through the joint scientific consultation (JSC). By reducing duplication of effort among member states and facilitating early dialogue between stakeholders, the regulation ultimately seeks to accelerate patient access to innovative treatments. By fostering greater collaboration and consistency in HTA evaluations, the new framework is expected to reduce the administrative burden for pharmaceutical companies while supporting more equitable access to medicines across the EU.
Key challenges and opportunities
- Right to be heard: A primary concern highlighted by both experts is ensuring that smaller companies can access JSCs. As noted by Natz, “It’s crucial that smaller companies have opportunities for joint scientific consultations to align clinical trial designs with HTA expectations.” He emphasized, “The right to be heard is the key issue in any HTA procedure.” However, the current limitations on the number of available JSC slots may hinder this process.
- Resource limitations: Both the industry and HTA bodies face resource constraints. There is a pressing need for increased slots for JSCs and improved coordination among national HTA institutions to leverage collective expertise. Natz pointed out, “It’s about the lack of resources… the HTA bodies and the coordination group seem not to have the resources to actually bring people into not just doing the evaluations in the JCA but also doing the JSCs.”
- Learning system: The EU HTA is envisioned as a learning system involving manufacturers, patient organizations, and physician groups. Continuous dialogue is vital for improving the regulation's implementation. As Altmann stated, “It’s important to go into this dialogue so that every participant can learn and improve the system.”
National and regional implications
However, as noted, the regulation also aims to streamline processes in larger countries. Both experts expressed optimism about the impact of the JCA reports, highlighting that they would be surprised if the JCA report is not respected at the national level, given the resources dedicated to its creation.
Future directions and considerations
Ensuring that patient and industry voices are integral to the decision-making process is crucial. Natz stated, “It’s very important that industry gets a voice in this interaction because, based on my experience with many manufacturers, they don't really feel heard in this process.” This involvement will help tailor the regulation to meet the diverse needs of stakeholders across Europe.
As the EU HTA regulation takes shape, the next five years will be pivotal in determining its success. By addressing challenges, leveraging opportunities, and fostering collaboration among stakeholders, the regulation has the potential to significantly enhance patient access to innovative medicines across Europe.
The dialogue from Pharma 2025 underscores the importance of these efforts and the collective commitment to improving healthcare outcomes. Altmann encapsulated this vision by stating, "If we get the EU HTA right, we can create a competitive advantage for Europe in the global market for innovative medicines."

Watch the full conversation
The contents of this piece contain marketing statements and do not include legal advice.
Entrez en contact avec notre équipe

Ressources connexes
Cencora.com fournit des traductions automatiques pour faciliter la lecture du site Web dans des langues autres que l’anglais. Pour ces traductions, des efforts raisonnables ont été faits pour fournir une traduction précise, cependant, aucune traduction automatique n’est parfaite et n’est pas destinée à remplacer les traducteurs humains. Ces traductions sont fournies à titre de service aux utilisateurs de Cencora.com et sont fournies « en l’état ». Aucune garantie d’aucune sorte, expresse ou implicite, n’est donnée quant à l’exactitude, la fiabilité ou l’exactitude de l’une ou l’autre de ces traductions effectuées de l’anglais vers une autre langue. Certains contenus (tels que les images, les vidéos, Flash, etc.) peuvent ne pas être traduits avec précision en raison des limitations du logiciel de traduction.
Toute divergence ou différence créée lors de la traduction de ce contenu de l’anglais vers une autre langue n’est pas contraignante et n’a aucun effet juridique pour la conformité, l’application ou toute autre fin. Si des erreurs sont identifiées, veuillez nouscontacter. Si vous avez des questions concernant l’exactitude des informations contenues dans ces traductions, veuillez vous référer à la version anglaise de la page.